HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

BACKGROUND: Triple negative breast cancer (TNBC) represents a significant clinical challenge. Chemotherapy remains the mainstay for a large part of TNBC patients, whereas drug resistance and tumor recurrence frequently occur. It is in urgent need to identify novel molecular targets for TNBC and deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Hui, Shen, Fei, Ruan, Sanbao, Tan, Congcong, Zhou, Jundong, Thor, Ann D., Liu, Bolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504712/
https://www.ncbi.nlm.nih.gov/pubmed/37716943
http://dx.doi.org/10.1186/s12935-023-03055-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504712/
https://www.ncbi.nlm.nih.gov/pubmed/37716943
http://dx.doi.org/10.1186/s12935-023-03055-w

Ejemplares similares